Company Overview
Bio Green Med Solution, Inc. operates as a distributor and developer focused on protective and fire safety materials, equipment, and fire protection systems, while simultaneously conducting research and development efforts in the pharmaceutical sector. The company functions within the healthcare sector, specifically the biotechnology industry, which implies a strategic positioning that bridges infrastructure safety solutions with innovative drug discovery capabilities. In terms of scale, the organization maintains a market capitalization of $2.94M and generated annual revenue of $81,000, with no specific employee count disclosed in available records. These financial figures indicate that the company occupies a very small position in the broader market, characterized by a micro-cap status where valuation is highly sensitive to modest fluctuations in revenue or strategic development milestones rather than established cash flows.
Financial Health
The company reported a revenue of $81,000 for the trailing twelve months, accompanied by a net income of $-6,974,000 and an EBITDA of $-9,171,000. The substantial gap between the nominal revenue and the significant negative net income reveals an extremely aggressive cost structure where expenses vastly exceed earnings, a common characteristic in early-stage biotechnology firms burning through capital for research. Free cash flow stands at $-9,983,125, indicating that the company is consuming cash reserves at a rapid pace, which limits its current financial flexibility to fund operations without external capital injections. All three margin metrics reflect this financial strain, with a gross margin of 0.0%, an operating margin of -1224.7%, and a profit margin of 0.0%, suggesting that the company has not yet achieved profitability on its sales or operations. The balance sheet shows a cash position of $3.84M against a debt load of $5,000, resulting in a debt-to-equity ratio of 0.07, which indicates a highly conservative capital structure with negligible leverage. Liquidity is strong in the short term, evidenced by a current ratio of 6.43, meaning the company holds ample current assets to cover its current liabilities. However, the return on equity is -177.6% and the return on assets is -84.7%, metrics that reveal management has not yet generated positive returns on the capital invested in the business.
Valuation Assessment
Trailing P/E and forward P/E ratios are both listed as N/A, a condition that implies the company has not generated sufficient earnings to support a traditional multiple-based valuation and suggests an earnings trajectory that is currently negative or non-existent. The price-to-book ratio is recorded at 0.49, indicating that the market values the company at less than its net asset value, which often occurs in distressed or high-risk biotechnology situations where intangible assets are undervalued on the books. Alternative valuation metrics include a price-to-sales ratio of 36.27 and an EV/EBITDA of -0.12, suggesting that the market is pricing the company based on future potential rather than current profitability, despite the high multiple relative to sales. The stock has a 52-week high of $100.80 and a 52-week low of $0.73, and given the market cap of $2.94M and the volatility inherent in micro-caps, the current price sits in a range that reflects extreme sensitivity to market sentiment. The beta value is -0.48, which is an anomalous negative figure indicating that the stock's price volatility moves inversely to the broader market, though the magnitude suggests significant instability rather than a standard inverse correlation.
Growth & Income
Revenue growth year-over-year is recorded at 710.0%, while earnings growth is N/A, implying that while top-line sales have expanded dramatically, the company has not yet turned those sales into profitable earnings. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which means the company reinvests all available capital into its research, development, and operational scaling rather than distributing income to shareholders. The overall growth and income profile is characterized by explosive revenue expansion that has not yet been matched by earnings growth, creating a scenario where the company relies entirely on capital markets to fund its expansion and cover its substantial operating losses. This profile is typical for pre-revenue or pre-profit biotechnology entities where the primary focus remains on advancing pharmaceutical research and establishing the protective materials business before achieving sustainable profitability.